Publications 2024

Lereim RR, Dunn C, Aamdal E, Chauhan SK, Straume O, Guren TK, Kyte JA (2024)
Plasma protein dynamics during ipilimumab treatment in metastatic melanoma: associations with tumor response, adverse events and survival
Oncoimmunology, 14 (1), 2440967
DOI 10.1080/2162402X.2024.2440967, PubMed 39703053

Publications 2022

Ellingsen EB, Bounova G, Kerzeli I, Anzar I, Simnica D, Aamdal E, Guren T, Clancy T, Mezheyeuski A, Inderberg EM, Mangsbo SM, Binder M, Hovig E, Gaudernack G (2022)
Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination
J Transl Med, 20 (1), 419
DOI 10.1186/s12967-022-03624-z, PubMed 36089578

Ellingsen EB, Aamdal E, Guren T, Lilleby W, Brunsvig PF, Mangsbo SM, Aamdal S, Hovig E, Mensali N, Gaudernack G, Inderberg EM (2022)
Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials
J Immunother Cancer, 10 (5)
DOI 10.1136/jitc-2021-004345, PubMed 35613827

Aamdal E, Skovlund E, Jacobsen KD, Straume O, Kersten C, Herlofsen O, Karlsen J, Hussain I, Amundsen A, Dalhaug A, Nyakas M, Hagene KT, Holmsen K, Aamdal S, Kaasa S, Guren TK, Kyte JA (2022)
Health-related quality of life in patients with advanced melanoma treated with ipilimumab: prognostic implications and changes during treatment
ESMO Open, 7 (5), 100588
DOI 10.1016/j.esmoop.2022.100588, PubMed 36116420

Publications 2021

Aamdal E, Inderberg EM, Ellingsen EB, Rasch W, Brunsvig PF, Aamdal S, Heintz KM, Vodák D, Nakken S, Hovig E, Nyakas M, Guren TK, Gaudernack G (2021)
Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial
Front Immunol, 12, 663865
DOI 10.3389/fimmu.2021.663865, PubMed 34046035

Aamdal E, Jacobsen KD, Straume O, Kersten C, Herlofsen O, Karlsen J, Hussain I, Amundsen A, Dalhaug A, Nyakas M, Schuster C, Hagene KT, Holmsen K, Russnes HG, Skovlund E, Kaasa S, Aamdal S, Kyte JA, Guren TK (2021)
Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-up
Int J Cancer, 150 (1), 100-111
DOI 10.1002/ijc.33768, PubMed 34449877

Publications 2019

Nyakas M, Aamdal E, Jacobsen KD, Guren TK, Aamdal S, Hagene KT, Brunsvig P, Yndestad A, Halvorsen B, Tasken KA, Aukrust P, Maelandsmo GM, Ueland T (2019)
Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
Clin Exp Immunol, 197 (1), 74-82
DOI 10.1111/cei.13283, PubMed 30821848

Publications 2016

Aamdal E (2016)
What is cancer exactly?
Tidsskr. Nor. Laegeforen., 136 (20), 1746
DOI 10.4045/tidsskr.16.0721